Provectus Announces Acceptance of PV-10 Poster Presentations at SMR 2019 Congress
September 24, 2019 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10® in combination...
Provectus Names Harold Schmitz, PhD to Company's Scientific Advisory Board
September 11, 2019 07:00 ET
|
Provectus Biopharmaceuticals Inc.
Dr. Schmitz, General Partner of The March Fund and former Chief Science Officer of Mars, Incorporated is Provectus’ inaugural Scientific Advisory Board member KNOXVILLE, TN, Sept. 11, 2019 (GLOBE...
Provectus Names Frank Akers, PhD to Company’s Strategic Advisory Board
July 29, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Dr. Akers to assist Provectus develop and manage new Company scientific advisory board KNOXVILLE, TN, July 29, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of...
Provectus Receives Notice of Allowance for Fourth Cancer Combination Therapy Patent from the United States Patent and Trademark Office
July 15, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
- Further patent protection of combinations of intratumoral PV-10 and checkpoint inhibitor (CI) drugs for the treatment of multiple, different, solid tumor cancers KNOXVILLE, TN, July 15, 2019 ...
Provectus Biopharmaceuticals Announces Acceptances of PV-10 Poster Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
April 17, 2019 16:05 ET
|
Provectus Biopharmaceuticals Inc.
Metastatic neuroendocrine tumors; Advanced cutaneous melanomaIntratumoral administration of PV-10 to visceral and superficial disease locationsSingle-agent and combination therapy treatment settings ...
Provectus Provides Update on Metastatic Uveal Melanoma Clinical Development Program for Investigational Drug PV-10
March 21, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 21, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead investigational...
ARTICLE COMPARING SURVIVAL OUTCOMES OF ISOLATED LIMB INFUSION VERSUS PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
January 29, 2019 08:30 ET
|
Provectus Biopharmaceuticals Inc.
- 72 patients were treated with either ILI or PV-10 at Australia’s Princess Alexandra Hospital; data were prospectively recorded; primary outcome was melanoma-specific survival; ILI is historical...
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON MELANOMA CLINICAL DEVELOPMENT PROGRAM FOR INVESTIGATIONAL DRUG PV-10
December 06, 2018 08:30 ET
|
Provectus Biopharmaceuticals Inc.
Lesion-level response data from main cohort of advanced melanoma patients naïve to immune checkpoint inhibition in Phase 1b/2 combination study of PV-10 and KEYTRUDA® (pembrolizumab) presented at...
University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur
November 12, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATIONS AT SMR 2018 CONGRESS
September 11, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from two ongoing clinical trials, single agent PV-10 and PV-10 in combination with checkpoint...